"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","treatment_protocol_ch1","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_email","contact_phone","contact_laboratory","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count"
"GSM657620","Ovarian Cancer SO300","GSM657620","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 0.36","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657620/GSM657620_SO300.CEL.gz","22283"
"GSM657643","Ovarian Cancer SO401","GSM657643","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 1.48","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657643/GSM657643_SO401.CEL.gz","22283"
"GSM657526","Normal HOSE2228","GSM657526","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian surface epithelial cells","Homo sapiens","tissue: Normal ovarian surface epithelium","","","","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from ovarian surface epithelial cells","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657526/GSM657526_HOSE2228.CEL.gz","22283"
"GSM657666","Ovarian Cancer SO489","GSM657666","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 5.41","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657666/GSM657666_SO489.CEL.gz","22283"
"GSM657689","Ovarian Cancer SO613","GSM657689","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 6.54","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657689/GSM657689_SO613.CEL.gz","22283"
"GSM657672","Ovarian Cancer SO504","GSM657672","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: NED (no evidence of disease)","survival years: 11.78","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657672/GSM657672_SO504.CEL.gz","22283"
"GSM657574","Ovarian Cancer SO205","GSM657574","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 1.89","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657574/GSM657574_SO205.CEL.gz","22283"
"GSM657597","Ovarian Cancer SO247","GSM657597","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 5.34","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657597/GSM657597_SO247.CEL.gz","22283"
"GSM657626","Ovarian Cancer SO322","GSM657626","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.99","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657626/GSM657626_SO322.CEL.gz","22283"
"GSM657543","Ovarian Cancer SO124","GSM657543","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 3.26","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657543/GSM657543_SO124.CEL.gz","22283"
"GSM657637","Ovarian Cancer SO388","GSM657637","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.97","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657637/GSM657637_SO388.CEL.gz","22283"
"GSM657589","Ovarian Cancer SO235","GSM657589","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.62","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657589/GSM657589_SO235.CEL.gz","22283"
"GSM657580","Ovarian Cancer SO218","GSM657580","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 4.6","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657580/GSM657580_SO218.CEL.gz","22283"
"GSM657534","Ovarian Cancer SO11","GSM657534","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.51","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657534/GSM657534_SO11.CEL.gz","22283"
"GSM657683","Ovarian Cancer SO603","GSM657683","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.25","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657683/GSM657683_SO603.CEL.gz","22283"
"GSM657537","Ovarian Cancer SO116","GSM657537","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 3.58","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657537/GSM657537_SO116.CEL.gz","22283"
"GSM657700","Ovarian Cancer SO78","GSM657700","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.94","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657700/GSM657700_SO78.CEL.gz","22283"
"GSM657520","Normal HOSE2008","GSM657520","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian surface epithelial cells","Homo sapiens","tissue: Normal ovarian surface epithelium","","","","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from ovarian surface epithelial cells","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657520/GSM657520_HOSE2008.CEL.gz","22283"
"GSM657649","Ovarian Cancer SO420b","GSM657649","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.1","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657649/GSM657649_SO420b.CEL.gz","22283"
"GSM657663","Ovarian Cancer SO481","GSM657663","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 4.88","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657663/GSM657663_SO481.CEL.gz","22283"
"GSM657712","Ovarian Cancer SO91","GSM657712","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 4.63","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657712/GSM657712_SO91.CEL.gz","22283"
"GSM657706","Ovarian Cancer SO84","GSM657706","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.12","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657706/GSM657706_SO84.CEL.gz","22283"
"GSM657606","Ovarian Cancer SO263","GSM657606","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 3.93","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657606/GSM657606_SO263.CEL.gz","22283"
"GSM657563","Ovarian Cancer SO187","GSM657563","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 2.48","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657563/GSM657563_SO187.CEL.gz","22283"
"GSM657557","Ovarian Cancer SO173","GSM657557","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 2.71","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657557/GSM657557_SO173.CEL.gz","22283"
"GSM657657","Ovarian Cancer SO429","GSM657657","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.53","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657657/GSM657657_SO429.CEL.gz","22283"
"GSM657692","Ovarian Cancer SO69","GSM657692","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 4.55","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657692/GSM657692_SO69.CEL.gz","22283"
"GSM657623","Ovarian Cancer SO308","GSM657623","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 4.83","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657623/GSM657623_SO308.CEL.gz","22283"
"GSM657617","Ovarian Cancer SO290","GSM657617","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.5","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657617/GSM657617_SO290.CEL.gz","22283"
"GSM657546","Ovarian Cancer SO131","GSM657546","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 2.94","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657546/GSM657546_SO131.CEL.gz","22283"
"GSM657600","Ovarian Cancer SO250","GSM657600","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 8.64","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657600/GSM657600_SO250.CEL.gz","22283"
"GSM657669","Ovarian Cancer SO500","GSM657669","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.33","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657669/GSM657669_SO500.CEL.gz","22283"
"GSM657523","Normal HOSE2085","GSM657523","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian surface epithelial cells","Homo sapiens","tissue: Normal ovarian surface epithelium","","","","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from ovarian surface epithelial cells","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657523/GSM657523_HOSE2085.CEL.gz","22283"
"GSM657646","Ovarian Cancer SO409","GSM657646","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.68","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657646/GSM657646_SO409.CEL.gz","22283"
"GSM657686","Ovarian Cancer SO609","GSM657686","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 5.63","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657686/GSM657686_SO609.CEL.gz","22283"
"GSM657577","Ovarian Cancer SO214","GSM657577","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.96","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657577/GSM657577_SO214.CEL.gz","22283"
"GSM657640","Ovarian Cancer SO396","GSM657640","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.69","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657640/GSM657640_SO396.CEL.gz","22283"
"GSM657629","Ovarian Cancer SO342","GSM657629","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.89","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657629/GSM657629_SO342.CEL.gz","22283"
"GSM657540","Ovarian Cancer SO12","GSM657540","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 0.71","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657540/GSM657540_SO12.CEL.gz","22283"
"GSM657586","Ovarian Cancer SO23","GSM657586","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 6.91","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657586/GSM657586_SO23.CEL.gz","22283"
"GSM657583","Ovarian Cancer SO227","GSM657583","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 5.68","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657583/GSM657583_SO227.CEL.gz","22283"
"GSM657703","Ovarian Cancer SO80","GSM657703","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 4.46","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657703/GSM657703_SO80.CEL.gz","22283"
"GSM657680","Ovarian Cancer SO59","GSM657680","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.03","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657680/GSM657680_SO59.CEL.gz","22283"
"GSM657709","Ovarian Cancer SO87","GSM657709","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 4.74","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657709/GSM657709_SO87.CEL.gz","22283"
"GSM657603","Ovarian Cancer SO258","GSM657603","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.72","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657603/GSM657603_SO258.CEL.gz","22283"
"GSM657566","Ovarian Cancer SO193","GSM657566","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 2.27","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657566/GSM657566_SO193.CEL.gz","22283"
"GSM657554","Ovarian Cancer SO16","GSM657554","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 6.29","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657554/GSM657554_SO16.CEL.gz","22283"
"GSM657660","Ovarian Cancer SO46","GSM657660","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.82","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657660/GSM657660_SO46.CEL.gz","22283"
"GSM657609","Ovarian Cancer SO268","GSM657609","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 9.22","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657609/GSM657609_SO268.CEL.gz","22283"
"GSM657560","Ovarian Cancer SO181","GSM657560","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 2.1","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657560/GSM657560_SO181.CEL.gz","22283"
"GSM657549","Ovarian Cancer SO137","GSM657549","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.17","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657549/GSM657549_SO137.CEL.gz","22283"
"GSM657641","Ovarian Cancer SO4","GSM657641","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 0.82","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657641/GSM657641_SO4.CEL.gz","22283"
"GSM657624","Ovarian Cancer SO31","GSM657624","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 4.12","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657624/GSM657624_SO31.CEL.gz","22283"
"GSM657618","Ovarian Cancer SO295","GSM657618","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 3.24","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657618/GSM657618_SO295.CEL.gz","22283"
"GSM657595","Ovarian Cancer SO244","GSM657595","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.99","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657595/GSM657595_SO244.CEL.gz","22283"
"GSM657695","Ovarian Cancer SO71","GSM657695","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 4.67","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657695/GSM657695_SO71.CEL.gz","22283"
"GSM657572","Ovarian Cancer SO201","GSM657572","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 2.06","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657572/GSM657572_SO201.CEL.gz","22283"
"GSM657532","Ovarian Cancer SO106","GSM657532","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 1.72","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657532/GSM657532_SO106.CEL.gz","22283"
"GSM657687","Ovarian Cancer SO61","GSM657687","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 5.8","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657687/GSM657687_SO61.CEL.gz","22283"
"GSM657578","Ovarian Cancer SO216","GSM657578","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.75","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657578/GSM657578_SO216.CEL.gz","22283"
"GSM657541","Ovarian Cancer SO121","GSM657541","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 3.3","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657541/GSM657541_SO121.CEL.gz","22283"
"GSM657635","Ovarian Cancer SO38","GSM657635","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.74","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657635/GSM657635_SO38.CEL.gz","22283"
"GSM657681","Ovarian Cancer SO60","GSM657681","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.18","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657681/GSM657681_SO60.CEL.gz","22283"
"GSM657584","Ovarian Cancer SO228","GSM657584","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 6.75","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657584/GSM657584_SO228.CEL.gz","22283"
"GSM657632","Ovarian Cancer SO362","GSM657632","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.55","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657632/GSM657632_SO362.CEL.gz","22283"
"GSM657561","Ovarian Cancer SO184","GSM657561","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 2.43","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657561/GSM657561_SO184.CEL.gz","22283"
"GSM657704","Ovarian Cancer SO82","GSM657704","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.81","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657704/GSM657704_SO82.CEL.gz","22283"
"GSM657655","Ovarian Cancer SO428","GSM657655","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.62","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657655/GSM657655_SO428.CEL.gz","22283"
"GSM657555","Ovarian Cancer SO166","GSM657555","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 2.93","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657555/GSM657555_SO166.CEL.gz","22283"
"GSM657698","Ovarian Cancer SO76","GSM657698","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: NED (no evidence of disease)","survival years: 4.88","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657698/GSM657698_SO76RE.CEL.gz","22283"
"GSM657661","Ovarian Cancer SO475","GSM657661","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.19","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657661/GSM657661_SO475.CEL.gz","22283"
"GSM657604","Ovarian Cancer SO261","GSM657604","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.98","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657604/GSM657604_SO261.CEL.gz","22283"
"GSM657612","Ovarian Cancer SO278","GSM657612","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 4.53","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657612/GSM657612_SO278.CEL.gz","22283"
"GSM657644","Ovarian Cancer SO402","GSM657644","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: AWD (alive with disease)","survival years: 10.04","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657644/GSM657644_SO402.CEL.gz","22283"
"GSM657667","Ovarian Cancer SO490","GSM657667","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 10.73","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657667/GSM657667_SO490.CEL.gz","22283"
"GSM657552","Ovarian Cancer SO148","GSM657552","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.37","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657552/GSM657552_SO148.CEL.gz","22283"
"GSM657575","Ovarian Cancer SO21","GSM657575","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 0.56","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657575/GSM657575_SO21.CEL.gz","22283"
"GSM657569","Ovarian Cancer SO197","GSM657569","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 2.16","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657569/GSM657569_SO197.CEL.gz","22283"
"GSM657521","Normal HOSE2061","GSM657521","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian surface epithelial cells","Homo sapiens","tissue: Normal ovarian surface epithelium","","","","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from ovarian surface epithelial cells","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657521/GSM657521_HOSE2061.CEL.gz","22283"
"GSM657598","Ovarian Cancer SO249","GSM657598","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 6.83","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657598/GSM657598_SO249.CEL.gz","22283"
"GSM657621","Ovarian Cancer SO301","GSM657621","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.99","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657621/GSM657621_SO301.CEL.gz","22283"
"GSM657638","Ovarian Cancer SO393","GSM657638","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 3.95","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657638/GSM657638_SO393.CEL.gz","22283"
"GSM657675","Ovarian Cancer SO507","GSM657675","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 6.81","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657675/GSM657675_SO507.CEL.gz","22283"
"GSM657592","Ovarian Cancer SO241","GSM657592","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 3.12","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657592/GSM657592_SO241.CEL.gz","22283"
"GSM657529","Ovarian Cancer SO10","GSM657529","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 7.48","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657529/GSM657529_SO10.CEL.gz","22283"
"GSM657581","Ovarian Cancer SO224","GSM657581","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 3.18","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657581/GSM657581_SO224.CEL.gz","22283"
"GSM657684","Ovarian Cancer SO604","GSM657684","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.56","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657684/GSM657684_SO604.CEL.gz","22283"
"GSM657535","Ovarian Cancer SO113","GSM657535","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 3.77","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657535/GSM657535_SO113.CEL.gz","22283"
"GSM657538","Ovarian Cancer SO117","GSM657538","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 3.53","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657538/GSM657538_SO117.CEL.gz","22283"
"GSM657678","Ovarian Cancer SO57","GSM657678","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.88","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657678/GSM657678_SO57.CEL.gz","22283"
"GSM657701","Ovarian Cancer SO79","GSM657701","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: NED (no evidence of disease)","survival years: 4.89","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657701/GSM657701_SO79.CEL.gz","22283"
"GSM657601","Ovarian Cancer SO256","GSM657601","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.94","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657601/GSM657601_SO256.CEL.gz","22283"
"GSM657664","Ovarian Cancer SO483","GSM657664","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.4","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657664/GSM657664_SO483.CEL.gz","22283"
"GSM657652","Ovarian Cancer SO422b","GSM657652","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: NED (no evidence of disease)","survival years: 13.65","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657652/GSM657652_SO422b.CEL.gz","22283"
"GSM657615","Ovarian Cancer SO283","GSM657615","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.66","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657615/GSM657615_SO283.CEL.gz","22283"
"GSM657558","Ovarian Cancer SO174","GSM657558","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.84","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657558/GSM657558_SO174.CEL.gz","22283"
"GSM657707","Ovarian Cancer SO85","GSM657707","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.74","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657707/GSM657707_SO85.CEL.gz","22283"
"GSM657658","Ovarian Cancer SO434","GSM657658","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 1.98","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657658/GSM657658_SO434.CEL.gz","22283"
"GSM657647","Ovarian Cancer SO418","GSM657647","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 1.34","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657647/GSM657647_SO418.CEL.gz","22283"
"GSM657576","Ovarian Cancer SO211","GSM657576","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 4.94","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657576/GSM657576_SO211.CEL.gz","22283"
"GSM657570","Ovarian Cancer SO2","GSM657570","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.83","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657570/GSM657570_SO2.CEL.gz","22283"
"GSM657599","Ovarian Cancer SO25","GSM657599","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.5","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657599/GSM657599_SO25.CEL.gz","22283"
"GSM657593","Ovarian Cancer SO242","GSM657593","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.21","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657593/GSM657593_SO242.CEL.gz","22283"
"GSM657524","Normal HOSE2225","GSM657524","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian surface epithelial cells","Homo sapiens","tissue: Normal ovarian surface epithelium","","","","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from ovarian surface epithelial cells","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657524/GSM657524_HOSE2225.CEL.gz","22283"
"GSM657693","Ovarian Cancer SO7","GSM657693","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 5.4","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657693/GSM657693_SO7.CEL.gz","22283"
"GSM657670","Ovarian Cancer SO501","GSM657670","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 10.87","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657670/GSM657670_SO501.CEL.gz","22283"
"GSM657547","Ovarian Cancer SO134","GSM657547","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 1.03","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657547/GSM657547_SO134.CEL.gz","22283"
"GSM657530","Ovarian Cancer SO100","GSM657530","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 4.51","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657530/GSM657530_SO100.CEL.gz","22283"
"GSM657676","Ovarian Cancer SO509","GSM657676","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.84","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657676/GSM657676_SO509.CEL.gz","22283"
"GSM657639","Ovarian Cancer SO395","GSM657639","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.97","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657639/GSM657639_SO395.CEL.gz","22283"
"GSM657630","Ovarian Cancer SO347","GSM657630","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 7.85","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657630/GSM657630_SO347.CEL.gz","22283"
"GSM657587","Ovarian Cancer SO230","GSM657587","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.64","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657587/GSM657587_SO230.CEL.gz","22283"
"GSM657536","Ovarian Cancer SO115","GSM657536","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.45","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657536/GSM657536_SO115.CEL.gz","22283"
"GSM657633","Ovarian Cancer SO367","GSM657633","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 6.51","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657633/GSM657633_SO367.CEL.gz","22283"
"GSM657679","Ovarian Cancer SO58","GSM657679","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.8","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657679/GSM657679_SO58.CEL.gz","22283"
"GSM657702","Ovarian Cancer SO8","GSM657702","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 7.97","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657702/GSM657702_SO8.CEL.gz","22283"
"GSM657567","Ovarian Cancer SO194","GSM657567","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 2.23","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657567/GSM657567_SO194.CEL.gz","22283"
"GSM657710","Ovarian Cancer SO88","GSM657710","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: NED (no evidence of disease)","survival years: 4.76","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657710/GSM657710_SO88.CEL.gz","22283"
"GSM657616","Ovarian Cancer SO285","GSM657616","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.32","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657616/GSM657616_SO285.CEL.gz","22283"
"GSM657553","Ovarian Cancer SO154","GSM657553","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: AWD (alive with disease)","survival years: 3.7","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657553/GSM657553_SO154.CEL.gz","22283"
"GSM657659","Ovarian Cancer SO44","GSM657659","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: NED (no evidence of disease)","survival years: 6.32","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657659/GSM657659_SO44.CEL.gz","22283"
"GSM657653","Ovarian Cancer SO423","GSM657653","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: AWD (alive with disease)","survival years: 13.46","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657653/GSM657653_SO423.CEL.gz","22283"
"GSM657610","Ovarian Cancer SO272","GSM657610","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 3.75","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657610/GSM657610_SO272.CEL.gz","22283"
"GSM657573","Ovarian Cancer SO203","GSM657573","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 1.59","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657573/GSM657573_SO203.CEL.gz","22283"
"GSM657550","Ovarian Cancer SO141","GSM657550","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.47","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657550/GSM657550_SO141.CEL.gz","22283"
"GSM657690","Ovarian Cancer SO67","GSM657690","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.79","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657690/GSM657690_SO67.CEL.gz","22283"
"GSM657527","Normal HOSE2230","GSM657527","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian surface epithelial cells","Homo sapiens","tissue: Normal ovarian surface epithelium","","","","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from ovarian surface epithelial cells","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657527/GSM657527_HOSE2230.CEL.gz","22283"
"GSM657713","Ovarian Cancer SO94","GSM657713","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 3.73","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657713/GSM657713_SO94.CEL.gz","22283"
"GSM657696","Ovarian Cancer SO73","GSM657696","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: AWD (alive with disease)","survival years: 5.27","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657696/GSM657696_SO73.CEL.gz","22283"
"GSM657619","Ovarian Cancer SO299","GSM657619","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.06","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657619/GSM657619_SO299.CEL.gz","22283"
"GSM657596","Ovarian Cancer SO246","GSM657596","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.95","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657596/GSM657596_SO246.CEL.gz","22283"
"GSM657673","Ovarian Cancer SO505","GSM657673","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 11.59","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657673/GSM657673_SO505.CEL.gz","22283"
"GSM657544","Ovarian Cancer SO129","GSM657544","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 2.82","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657544/GSM657544_SO129.CEL.gz","22283"
"GSM657627","Ovarian Cancer SO325","GSM657627","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.31","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657627/GSM657627_SO325.CEL.gz","22283"
"GSM657590","Ovarian Cancer SO236","GSM657590","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 13.5","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657590/GSM657590_SO236.CEL.gz","22283"
"GSM657636","Ovarian Cancer SO387","GSM657636","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 1.47","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657636/GSM657636_SO387.CEL.gz","22283"
"GSM657533","Ovarian Cancer SO108","GSM657533","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 3.99","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657533/GSM657533_SO108.CEL.gz","22283"
"GSM657682","Ovarian Cancer SO600","GSM657682","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 8.82","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657682/GSM657682_SO600.CEL.gz","22283"
"GSM657656","Ovarian Cancer SO428b","GSM657656","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.74","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657656/GSM657656_SO428b.CEL.gz","22283"
"GSM657662","Ovarian Cancer SO479","GSM657662","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 5.9","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657662/GSM657662_SO479.CEL.gz","22283"
"GSM657650","Ovarian Cancer SO421","GSM657650","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.57","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657650/GSM657650_SO421.CEL.gz","22283"
"GSM657556","Ovarian Cancer SO17","GSM657556","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 3.83","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657556/GSM657556_SO17.CEL.gz","22283"
"GSM657699","Ovarian Cancer SO77","GSM657699","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.71","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657699/GSM657699_SO77.CEL.gz","22283"
"GSM657613","Ovarian Cancer SO279","GSM657613","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.92","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657613/GSM657613_SO279.CEL.gz","22283"
"GSM657564","Ovarian Cancer SO189","GSM657564","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 2.3","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657564/GSM657564_SO189.CEL.gz","22283"
"GSM657607","Ovarian Cancer SO265","GSM657607","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.33","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657607/GSM657607_SO265.CEL.gz","22283"
"GSM657668","Ovarian Cancer SO5","GSM657668","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 7.43","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657668/GSM657668_SO5.CEL.gz","22283"
"GSM657691","Ovarian Cancer SO68","GSM657691","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 5.43","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657691/GSM657691_SO68.CEL.gz","22283"
"GSM657551","Ovarian Cancer SO143","GSM657551","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 6.86","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657551/GSM657551_SO143.CEL.gz","22283"
"GSM657528","Normal HOSE2234","GSM657528","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian surface epithelial cells","Homo sapiens","tissue: Normal ovarian surface epithelium","","","","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from ovarian surface epithelial cells","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657528/GSM657528_HOSE2234.CEL.gz","22283"
"GSM657622","Ovarian Cancer SO303","GSM657622","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 1.55","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657622/GSM657622_SO303.CEL.gz","22283"
"GSM657545","Ovarian Cancer SO13","GSM657545","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: NED (no evidence of disease)","survival years: 7.33","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657545/GSM657545_SO13.CEL.gz","22283"
"GSM657522","Normal HOSE2064","GSM657522","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian surface epithelial cells","Homo sapiens","tissue: Normal ovarian surface epithelium","","","","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from ovarian surface epithelial cells","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657522/GSM657522_HOSE2064.CEL.gz","22283"
"GSM657645","Ovarian Cancer SO404","GSM657645","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.59","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657645/GSM657645_SO404.CEL.gz","22283"
"GSM657674","Ovarian Cancer SO506","GSM657674","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.37","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657674/GSM657674_SO506.CEL.gz","22283"
"GSM657591","Ovarian Cancer SO237","GSM657591","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.59","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657591/GSM657591_SO237.CEL.gz","22283"
"GSM657685","Ovarian Cancer SO607","GSM657685","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 6.88","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657685/GSM657685_SO607.CEL.gz","22283"
"GSM657628","Ovarian Cancer SO334","GSM657628","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.35","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657628/GSM657628_SO334.CEL.gz","22283"
"GSM657582","Ovarian Cancer SO225","GSM657582","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 8.8","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657582/GSM657582_SO225.CEL.gz","22283"
"GSM657539","Ovarian Cancer SO118","GSM657539","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: AWD (alive with disease)","survival years: 3.49","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657539/GSM657539_SO118.CEL.gz","22283"
"GSM657651","Ovarian Cancer SO422","GSM657651","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.97","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657651/GSM657651_SO422.CEL.gz","22283"
"GSM657614","Ovarian Cancer SO282","GSM657614","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.4","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657614/GSM657614_SO282.CEL.gz","22283"
"GSM657602","Ovarian Cancer SO257","GSM657602","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.2","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657602/GSM657602_SO257.CEL.gz","22283"
"GSM657565","Ovarian Cancer SO190","GSM657565","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.16","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657565/GSM657565_SO190.CEL.gz","22283"
"GSM657708","Ovarian Cancer SO86","GSM657708","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: AWD (alive with disease)","survival years: 4.96","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657708/GSM657708_SO86RE.CEL.gz","22283"
"GSM657608","Ovarian Cancer SO267","GSM657608","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.3","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657608/GSM657608_SO267.CEL.gz","22283"
"GSM657559","Ovarian Cancer SO18","GSM657559","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 6.3","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657559/GSM657559_SO18.CEL.gz","22283"
"GSM657525","Normal HOSE2226","GSM657525","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian surface epithelial cells","Homo sapiens","tissue: Normal ovarian surface epithelium","","","","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from ovarian surface epithelial cells","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657525/GSM657525_HOSE2226.CEL.gz","22283"
"GSM657671","Ovarian Cancer SO502","GSM657671","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 8.46","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657671/GSM657671_SO502.CEL.gz","22283"
"GSM657665","Ovarian Cancer SO487","GSM657665","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 7.22","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657665/GSM657665_SO487.CEL.gz","22283"
"GSM657594","Ovarian Cancer SO243","GSM657594","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 13.1","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657594/GSM657594_SO243.CEL.gz","22283"
"GSM657648","Ovarian Cancer SO420","GSM657648","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 9.02","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657648/GSM657648_SO420.CEL.gz","22283"
"GSM657642","Ovarian Cancer SO400","GSM657642","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: NED (no evidence of disease)","survival years: 10.09","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657642/GSM657642_SO400.CEL.gz","22283"
"GSM657548","Ovarian Cancer SO135","GSM657548","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 3.55","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657548/GSM657548_SO135.CEL.gz","22283"
"GSM657694","Ovarian Cancer SO70","GSM657694","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 2.54","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657694/GSM657694_SO70.CEL.gz","22283"
"GSM657571","Ovarian Cancer SO200","GSM657571","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 2.15","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657571/GSM657571_SO200.CEL.gz","22283"
"GSM657579","Ovarian Cancer SO217","GSM657579","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.91","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657579/GSM657579_SO217.CEL.gz","22283"
"GSM657531","Ovarian Cancer SO103","GSM657531","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 4.38","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657531/GSM657531_SO103.CEL.gz","22283"
"GSM657625","Ovarian Cancer SO312","GSM657625","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.56","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657625/GSM657625_SO312.CEL.gz","22283"
"GSM657542","Ovarian Cancer SO122","GSM657542","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.3","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657542/GSM657542_SO122.CEL.gz","22283"
"GSM657688","Ovarian Cancer SO610","GSM657688","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 6.49","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657688/GSM657688_SO610.CEL.gz","22283"
"GSM657677","Ovarian Cancer SO511","GSM657677","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 1.66","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657677/GSM657677_SO511.CEL.gz","22283"
"GSM657588","Ovarian Cancer SO231","GSM657588","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 5.15","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657588/GSM657588_SO231.CEL.gz","22283"
"GSM657634","Ovarian Cancer SO375","GSM657634","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 8.12","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657634/GSM657634_SO375.CEL.gz","22283"
"GSM657631","Ovarian Cancer SO36","GSM657631","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: AWD (alive with disease)","survival years: 4.39","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657631/GSM657631_SO36RE.CEL.gz","22283"
"GSM657585","Ovarian Cancer SO229","GSM657585","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 0.86","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657585/GSM657585_SO229.CEL.gz","22283"
"GSM657562","Ovarian Cancer SO185","GSM657562","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: NED (no evidence of disease)","survival years: 2.37","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657562/GSM657562_SO185.CEL.gz","22283"
"GSM657519","Normal HOSE2237","GSM657519","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian surface epithelial cells","Homo sapiens","tissue: Normal ovarian surface epithelium","","","","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from ovarian surface epithelial cells","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657519/GSM657519_HOSE2237.CEL.gz","22283"
"GSM657697","Ovarian Cancer SO74","GSM657697","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 0.52","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657697/GSM657697_SO74.CEL.gz","22283"
"GSM657568","Ovarian Cancer SO196","GSM657568","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 1.28","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657568/GSM657568_SO196.CEL.gz","22283"
"GSM657711","Ovarian Cancer SO89","GSM657711","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: AWD (alive with disease)","survival years: 4.66","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657711/GSM657711_SO89.CEL.gz","22283"
"GSM657654","Ovarian Cancer SO426","GSM657654","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: AWD (alive with disease)","survival years: 13.5","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657654/GSM657654_SO426.CEL.gz","22283"
"GSM657611","Ovarian Cancer SO273","GSM657611","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Optimal","status: DOD (dead of disease)","survival years: 2.52","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657611/GSM657611_SO273.CEL.gz","22283"
"GSM657605","Ovarian Cancer SO262","GSM657605","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: DOD (dead of disease)","survival years: 7.88","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657605/GSM657605_SO262.CEL.gz","22283"
"GSM657705","Ovarian Cancer SO83","GSM657705","Public on Jan 20 2011","Jan 19 2011","Jan 20 2011","RNA","1","Ovarian tumor","Homo sapiens","tissue: Late-stage high-grade ovarian cancer","surgery outcome: Suboptimal","status: NED (no evidence of disease)","survival years: 4.9","Tumor specimens were obtained from 185 previously untreated late-stage (III–IV) high-grade ovarian cancer patients. A set of 10 normal ovarian surface epithelium (OSE) cytobrushing specimens were used as control","total RNA","Total RNA was isolated using the RNeasy Micro kit (Qiagen)","Biotin","Labeled amplified RNA (aRNA) for microarray analysis was generated from tumor or OSE-derived total RNA using a single round of amplification","9606","A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).","Array images were acquired using a GeneChip Scanner 3000 (Affymetrix)","Gene expression data from late-stage high-grade ovarian cancer","Robust Multi-Array Analysis was performed","GPL96","Michael,,Birrer","mbirrer@partners.org","6177244800","Surgical Oncology Research Labs","Medicine","MGH","70 Blossom Street","Boston","MA","02114","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM657nnn/GSM657705/GSM657705_SO83.CEL.gz","22283"
